Maverick Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Maverick Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-812	Closed	-$330K	–	554
2023 Q4	$330K	Sell	812 -645	-44%	-$238K	0.01%	257
2023 Q3	$507K	Buy	+1,457	New	+$510K	0.01%	177
2021 Q4	–	Sell	-18,052	Closed	-$3.27M	–	624
2021 Q3	$3.27M	Buy	+18,052	New	+$3.52M	0.03%	127
2021 Q2	–	Sell	-6,254	Closed	-$1.34M	–	859
2021 Q1	$1.34M	Buy	+6,254	New	+$1.37M	0.01%	202
2020 Q2	–	Sell	-460	Closed	-$109K	–	682
2020 Q1	$109K	Buy	+460	New	+$106K	﹤0.01%	435
2015 Q2	–	Sell	-524,867	Closed	-$61.9M	–	133
2015 Q1	$61.9M	Buy	+524,867	New	+$62.9M	1%	31

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Maverick Capital's VRTX Position: Q1 2024 in Review

Maverick Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 812 shares — an estimated $330K sold.

Maverick Capital first reported a position in VRTX in Q1 2015 and held it in 6 quarters. The position peaked at $61.9M in Q1 2015. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Maverick Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Maverick Capital sold 812 Vertex Pharmaceuticals shares in Q1 2024, an estimated $330K.
Maverick Capital first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 6 quarters.
Maverick Capital's Vertex Pharmaceuticals position peaked at $61.9M in Q1 2015.
1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Maverick Capital's 13F filing for Q1 2024, filed 15 May 2024.